prostate cancer

EU clears review of Xtandi in earlier-stage prostate cancer
EU clears review of Xtandi in earlier-stage prostate cancer
Pharmaphorum
EMA
Europe
Astellas
Pfizer
prostate cancer
Xtandi
Flag link:
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Reuters
Astellas
Medicare
prostate cancer
Xtandi
drug pricing
Inflation Reduction Act
Flag link:
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Exelixis
Ipsen
Carbometyx
prostate cancer
Flag link:
Arcus and Gilead terminate development for etrumadenant in prostate cancer
Arcus and Gilead terminate development for etrumadenant in prostate cancer
Clinical Trials Arena
Arcus Biosciences
Gilead Sciences
prostate cancer
etrumadenant
Flag link:
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
Flag link:
Astellas to withhold prostate cancer drug from contract pharmacies
Astellas to withhold prostate cancer drug from contract pharmacies
Beckers Hospital Review
Astellas
340B
Xtandi
prostate cancer
Flag link:
Sanofi blocks Sandoz's Jevtana generic in patent win
Sanofi blocks Sandoz's Jevtana generic in patent win
Fierce Pharma
Sanofi
Jevtana
generics
Sandoz
prostate cancer
legal
Flag link:
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med
Fierce Pharma
Pfizer
FDA
prostate cancer
Talzenna
AstraZeneca
PARP inhibitors
Merck
Flag link:
Clarity commences COMBAT theranostic prostate cancer trial in the US
Clarity commences COMBAT theranostic prostate cancer trial in the US
Drugs.com
Clarity Pharmaceuticals
clinical trials
radiopharmaceuticals
prostate cancer
Flag link:
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
BioPharma Dive
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Flag link:
This Startup Just Raised $90M To Fight Cancer
This Startup Just Raised $90M To Fight Cancer
Crunchbase
Convergent Therapeutics
funding
oncology
radiopharmaceuticals
prostate cancer
Flag link:
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Seeking Alpha
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Flag link:
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Fierce Biotech
Immunic
prostate cancer
psoriasis
MS
multiple sclerosis
celiac disease
Flag link:
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
drug pricing
NIH
march-in rights
Flag link:
Pfizer and Astellas report positive data from prostate cancer therapy trial
Pfizer and Astellas report positive data from prostate cancer therapy trial
Clinical Trials Arena
Pfizer
Astellas
prostate cancer
clinical trials
Enzalutamide
leuprolide
Flag link:
Novartis takes step toward expanding supply of in-demand cancer drug
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Novartis
Pluvicto
prostate cancer
Flag link:
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
prostate cancer
Flag link:
Merck reports two Phase 3 study misses for Keytruda
Merck reports two Phase 3 study misses for Keytruda
BioPharma Dive
Merck
clinical trials
Keytruda
prostate cancer
lung cancer
Flag link:
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
Fierce Pharma
JNJ
Akeega
prostate cancer
PARP inhibitors
Flag link:
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
Fierce Pharma
ASCO GU
Pfizer
Astellas
Xtandi
prostate cancer
Flag link:

Pages